|
Thomas A. Bologna joined Orchid Cellmark in April 2006. Mr. Bologna has 25 years of experience in growing diverse life sciences businesses. He was most recently was chief executive officer and president of Quorex Pharmaceuticals, a pre-clinical anti-infective company that he strengthened and reorganized by prioritizing its drug development efforts. Previously, he was chairman, president and chief executive officer of Nasdaq-listed Ostex International, which developed, manufactured and marketed laboratory and point-of-care products for the management of osteoporosis. Mr. Bologna oversaw a revitalization of Ostex, restructuring the company, introducing new products and establishing collaborations with major partners. These achievements set the stage for a later successful merger with Inverness Medical Innovations. Mr. Bologna also achieved a similar success at Gen-Probe Incorporated, where he served as chairman, president and chief executive officer during his seven-year tenure. Mr. Bologna directed its initial public offering, led a turnaround of the company and helped it achieve market leadership in the provision of innovative diagnostic products. Earlier, Mr. Bologna was president of the Diagnostic Instrument Systems and the Johnston Laboratories divisions at Becton Dickinson & Company. He began his career in healthcare at Warner Lambert, where he held positions of increasing responsibility, culminating as vice president of the Scientific Instrument Division of its subsidiary, American Optical Company. Mr. Bologna holds B.S. and M.B.A. degrees from New York University.
| 